I am a UK research scientist with special interests in studying how cells function and what happens in human diseases such as cancer and Alzheimer’s disease. I am currently working as a Senior Lecturer and Academic Laboratory Director at Canterbury Christ Church University. My role includes managing the Life Sciences Industry Liaison Lab based at Discovery Park, in Sandwich, Kent. I am also a honorary member of the University of Liverpool and an elected Alumni council member of the General Assembly at the University of Manchester. I have been always passionate and dedicated to science from an early age. My passion for research began during my undergraduate studies were I undertook a 1-year research training at Boehringer Mannheim (Roche Diagnostics) at Penzberg in Bavaria. My research project was focused on human gene therapy and understanding the processes to maximize gene delivery. My studies took me to Manchester where I undertook my PhD with the best basic scientists working on how proteins are made in the cell. My PhD was a CASE award supported by both the BBSRC and Pfizer. Ironically I undertook a 6-month training period with Pfizer at Sandwich, the same place were I work today. In my previous role, I worked in the Faculty of Medicine at the University of Limoges, France directing the research on the first chair of excellence on Lung cancer were I established the first biobank at Limoges. In the first 3 months of taking my position at the Life Sciences Industry Liaison Lab, we established a functioning laboratory from an empty shell. I identified and established new partners, this included applying for successful funding (Innovate UK) with startup companies. I recognize the need for industry and academia to work together, this is important if we are to make the necessary advances in medicine.
Research and knowledge exchange
Overview of research:
My research has led me to several areas of science from basic to complex science in respect to human diseases. I have a long-standing interest within cellular biology including understanding the molecular mechanisms that underlie membrane protein biosynthesis, post-translational modifications such as N-glycosylation and phosphorylation, the autophagy and proteasome-mediated degradation pathways, neurodegeneration and in recent times the environmental control of exosomes in lung cancer. This experience has given me a greater understanding of the complexities of homeostasis and cellular function which is necessary to understand the progression of cancer. My recent research has been targeted at studying the environmental control of exosomes in lung cancer. In these studies, we have identified the neurotensin receptor-3, sortilin to play a role in exosome biogenesis and deregulation of this process may contribute to tumour aggressiveness and metastasis in both non-small cell lung cancer (NSCLC) and uveal melanoma (UM).
Selected grant awards:
- Roy Castle Lung Cancer Foundation full application ‘Validation of a plasma exosomal miRNA diagnostic signature for lung cancer’ co-applicant (Prof. John Field and Dr. Lakis Liloglou) at the University of Liverpool, September 2017, £120k.
- Roy Castle Lung Cancer Foundation pilot application ‘Molecular profiling of lung cancer exosomes for development of early diagnostic strategies’co-applicant at the University of Liverpool, September 2015, £25k.
- North West Cancer Research (NWCR) grant award ‘Exosome biogenesis: the role of sortilin in cancer biology’co-applicant at the University of Liverpool, August 2015, £185k
Teaching and subject expertise
I teach and am a module leader on several undergraduate modules including Drug discovery, Moelcular biology, Microbiology, Advancing Chemistry and Biomolecular Sciences Research project.
Selected list of conference talks and posters:
- Jubilee Medical Research Centre ‘National Symposium in Clinical Medicine- Cancer Genetics’ 14th– 16thSeptember, 2017, Thrissur, India)
- Presented a 30-minute talk ‘Exosomes in cancer diagnostics’, inauguration and highlights of the conference.
- Weizmann Institute ‘Extracellular vesicles: friends and foes’ (7th-9thJune, 2016, Tel Aviv, Israel)
- International Society of Extracellular Vesicles (ISEV) ‘Annual meeting’ (4th-7thMay 2016, Rotterdam, The Netherlands)
- International Society of Extracellular Vesicles (ISEV) ‘Annual meeting’ (23rd– 26thApril 2015, Washington, USA)
- Grand Sud Ouest (GSO) ‘The 10thmeeting’ (16th– 17thOctober 2014, Toulouse, France)
- Gave a 25 minute talk and presented a poster
- SFI ‘The Colloque of Cytokines and Chemokines’ meeting (19th– 21stMay 2014, Le Croisic, France)
- Gave a 15 minute talk and presented a poster
- Biochemical Society ‘The biology and pathology of Tau and its role in tauopathies II’ meeting (8-10thJanuary 2012, Cambridge, UK)
- IPSEN ‘Protein Quality control in Neurodegenerative diseases’ meeting (9thMay 2011, Paris, FRANCE)
- 10th Alzheimer’s disease meeting (24thSeptember 2009, Nantes, FRANCE)
- North West Cell Biology consortium meeting (7thSeptember 2007, Liverpool, UK)
- Glycomics:Challenges and Technologies (28thNovember 2006, London)
- North West Cell Biology consortium meeting (12thSeptember 2006, Sheffield, UK)
- Bioscience 2006 (22nd– 28thJuly 2006, Glasgow, UK)
- FASEB Summer Research Conferences: Protein folding in the cell (31stJuly – 5thAugust 2004, Vermont, USA)
- BioScience 2004 (18th– 22ndJuly, Glasgow, UK)
- Protein Targeting: Euroconference on protein-protein interactions during protein translocation (26thSept – 1stOct 2003, Spa, Belgium)
- Presented a poster and awarded conference and travel expenses
- MembProt Net EU consortium meeting (4 – 6thApril 2002, Heidelberg, Germany)
- MembProt Net EU consortium meeting (24 – 26thMay 2001, Gothenburg, Sweden)
- Karolinska Institute (September 2001, Stockholm, Sweden)
Publications and research outputs
-Davies MP and Wilson CM. The role of autophagy in lung disease. Autophagy. In press 2017
-Sacco JJ, Al-Akhrass H, Wilson CM. Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. Curr Pharm Des. 2016;22(28):4374-85.
-Mir R, Karim S, Kamal MA, Wilson CM and Mirza Z*.Conotoxins: Structure, therapeutic potential and pharmacological applications. Curr Pharm Des. 2016; 22(5):582-9.
-Wilson CM, et al. The ins and outs of nanoparticle technology in neurodegenerative diseases and cancer. Curr Drug Metab. 2015;16(8):609-32.
-Wilson CM, Naves T, Vincent F, Melloni B, Bonnaud F, Lalloué F, Jauberteau MO. Sortilin mediates the release and transfer of exosomes in concert with two tyrosine kinase receptors. J Cell Sci. 2014 127:3983-97.
-Wilson CM, Magnaudeix A, Yardin C, Terro F. Autophagy dysfunction and its link to Alzheimer's disease and type II diabetes mellitus. CNS Neurol Disord Drug Targets. 2014 :226-46.
-Magnaudeix A, Wilson CM, Page, G, Léveque P, Labrousse, F, Corre-Delage, MD, Yardin C,and F Terro. PP2A blockade inhibits autophagy and causes intraneuronal accumulation of ubiquitinated proteins. Neurobiol Aging. 2013; 34(3):770-90.
-Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: Involvement in Alzheimer’s disease. Ageing Res Rev. 2013; 12(1):289-309.
-Wilson CM, Magnaudeix, A, Yardin, C and F Terro. DC2 and Keratinocyte-associated Protein 2 (KCP2), Subunits of the Oligosaccharyltransferase Complex, Are Regulators of the gamma-Secretase-directed Processing of Amyloid Precursor Protein (APP). J Biol Chem. 286(36):31080-91. 2011.
-Cross BCS, Callan AC, McKibbin C, Piacenti M, Roboti P, Rabu C, Wilson CM, Whitehead R, Flitsch S, Pool MR, Swanton E, High S, Eeyarestatin I is a global inhibitor of Sec61-mediated protein translocation at the endoplasmic reticulum. J. Cell Sci. 122(23):4393-400. 2009.
-Wilson CM, Roebuck QP, and High S. Ribophorin I regulates substrate delivery to the oligosaccharyltransferase core. PNAS USA, 2008, 105(28):9534-39.